Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeted Sequencing of Plasma-Derived vs. Urinary cfDNA from Patients with Triple-Negative Breast Cancer. | Cancers (Basel) | 2022 | 36077638 | PubTator, text mining | PubMed |
| Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing. | Hered Cancer Clin Pract | 2022 | 36076240 | PubTator, text mining | PubMed |
| Epigenetic inactivation of DNA repair genes as promising prognostic and predictive biomarkers in urothelial bladder carcinoma patients. | Mol Genet Genomics | 2022 | 36076047 | PubTator, text mining | PubMed |
| Breast cancer: an up-to-date review and future perspectives. | Cancer Commun (Lond) | 2022 | 36074908 | PubTator, text mining | PubMed |
| Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk. | Cancer Sci | 2022 | 36065483 | PubTator, text mining | PubMed |
| circ_0061265 competitively binds to microRNA-885-3p to promote the development of gastric cancer by upregulating AURKA expression. | Cancer Cell Int | 2022 | 36064409 | PubTator, text mining | PubMed |
| Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. | J Exp Clin Cancer Res | 2022 | 36050786 | PubTator, text mining | PubMed |
| Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. | Clin Cancer Res | 2022 | 36040493 | PubTator, text mining | PubMed |
| Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation. | Front Pharmacol | 2022 | 36034850 | PubTator, text mining | PubMed |
| Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma. | Genes (Basel) | 2022 | 36011309 | PubTator, text mining | PubMed |
| Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer. | Genes (Basel) | 2022 | 36011273 | PubTator, text mining | PubMed |
| BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. | Cancers (Basel) | 2022 | 36010882 | PubTator, text mining | PubMed |
| Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. | Diagnostics (Basel) | 2022 | 36010253 | PubTator, text mining | PubMed |
| Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. | Biomedicines | 2022 | 36009418 | PubTator, text mining | PubMed |
| LeMeDISCO is a computational method for large-scale prediction & molecular interpretation of disease comorbidity. | Commun Biol | 2022 | 36008469 | PubTator, text mining | PubMed |
| Mutational and splicing landscape in a cohort of 43,000 patients tested for hereditary cancer. | NPJ Genom Med | 2022 | 36008414 | PubTator, text mining | PubMed |
| Double heterozygous pathogenic variants prevalence in a cohort of patients with hereditary breast cancer. | Front Oncol | 2022 | 36003761 | PubTator, text mining | PubMed |
| Case Report: A rare case of familial lung cancer requiring pneumonectomy in three male siblings. | Front Oncol | 2022 | 35982978 | PubTator, text mining | PubMed |
| Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol. | BMJ Open | 2022 | 35981778 | PubTator, text mining | PubMed |
| Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis. | Biomed Res Int | 2022 | 35978646 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=46